Treace Medical Concepts (NASDAQ:TMCI - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.01, Zacks reports. The firm had revenue of $47.39 million during the quarter, compared to the consensus estimate of $47.08 million. Treace Medical Concepts had a negative return on equity of 45.66% and a negative net margin of 23.01%. Treace Medical Concepts updated its FY 2025 guidance to EPS.
Treace Medical Concepts Price Performance
NASDAQ:TMCI traded up $0.45 during mid-day trading on Friday, reaching $6.13. The stock had a trading volume of 916,488 shares, compared to its average volume of 265,786. The firm has a 50 day moving average price of $5.81 and a two-hundred day moving average price of $7.29. The stock has a market capitalization of $385.52 million, a P/E ratio of -7.76 and a beta of 0.68. Treace Medical Concepts has a one year low of $4.54 and a one year high of $10.79. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.36 and a current ratio of 4.50.
Institutional Trading of Treace Medical Concepts
A hedge fund recently bought a new stake in Treace Medical Concepts stock. AQR Capital Management LLC acquired a new stake in Treace Medical Concepts, Inc. (NASDAQ:TMCI - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 58,523 shares of the company's stock, valued at approximately $491,000. AQR Capital Management LLC owned about 0.09% of Treace Medical Concepts as of its most recent filing with the Securities & Exchange Commission. 84.08% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of brokerages have recently issued reports on TMCI. Truist Financial dropped their price target on Treace Medical Concepts from $9.50 to $8.00 and set a "hold" rating for the company in a research report on Friday, April 11th. Stifel Nicolaus dropped their target price on Treace Medical Concepts from $9.00 to $6.00 and set a "hold" rating for the company in a research report on Friday. Finally, UBS Group dropped their target price on Treace Medical Concepts from $8.60 to $6.50 and set a "neutral" rating for the company in a research report on Friday. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, Treace Medical Concepts has a consensus rating of "Hold" and an average price target of $9.83.
Read Our Latest Stock Analysis on Treace Medical Concepts
About Treace Medical Concepts
(
Get Free Report)
Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Treace Medical Concepts, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Treace Medical Concepts wasn't on the list.
While Treace Medical Concepts currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.